References
- GOLD Executive Committee. Global Strategy for the Diagnosis Management, and Prevention of Chronic Obstructive Pulmonary Disease: Global Initiative for Chronic Obstructive Lung Disease, 2006
- Rodriguez-Roisin R. Toward a consensus definition for COPD exacerbations. Chest 2000;117:398-401S
- Donaldson GC, Seemungal TA, Bhowmik A, et al. Relationship between exacerbation frequency and lung function decline in chronic obstructive pulmonary diseases. Thorax 2002;57:847-52
- Niewoehner DE. The impact of severe exacerbations on quality of life and the clinical course of chronic obstructive pulmonary disease. Am J Med 2006;119:38-45
- Donaldson GC, Wedzicha JA. COPD exacerbations 1: epidemiology. Thorax 2006;61:164-8
- O'Donnell DE, Parker CM. COPD exacerbations. 3: Pathophysiology. Thorax 2006;61:354-61
- Wedzicha JA, Donaldson GC. Exacerbations of chronic obstructive pulmonary disease. Respir Care 2003;48:1204-15
- Seemungal TAR, Donaldson GC, Paul EA, et al. Effect of exacerbation on quality of life in patients with chronic obstructive pulmonary disease. Am J Respir Crit Care Med 1998;157:1418-22
- Simoens S, Decramer M. Pharmacoeconomics of the management of acute exacerbations of chronic obstructive pulmonary disease. Expert Opin Pharmacother 2007;8:633-48
- van Grunsven PM, van Schayck CP, Derenne JP, et al. Long term effects of inhaled corticosteroids in chronic obstructive pulmonary disease: a meta-analysis. Thorax 1999;54:7-14
- Sin DD, McAlister FA, Man SF, et al. Contemporary management of chronic obstructive pulmonary disease: scientific review. JAMA 2003;290:2301-12
- Gartlehner G, Hansen RA, Carson SS, et al. Efficacy and safety of inhaled corticosteroids in patients with COPD: a systematic review and meta-analysis of health outcomes. Ann Fam Med 2006;4:253-62
- Salpeter SR, Buckley NS, Salpeter EE. Meta-analysis: anticholinergics, but not beta-agonists, reduce severe exacerbations and respiratory mortality in COPD. J Gen Intern Med 2006;21:1011-19
- Rodrigo GJ, Nannini LJ, Rodríguez-Roisin R. Safety of long-acting beta-agonists in stable COPD: a systematic review. Chest 2008;133:1079-87
- Calverly PMA, Anderson JA, Celli B. Salmeterol and fluticasone propionate and survival in chronic obstructive pulmonary disease. N Engl J Med 2007;356:775-89
- Aaron SD, Fergusson D, Marks GB, et al. Counting, analysing and reporting exacerbations of COPD in randomised controlled trials. Thorax 2008;63:122-8
- Aaron SD, Vandemheen KL, Fergusson D, et al. Tiotropium in combination with placebo, salmeterol, or fluticasone-salmeterol for treatment of chronic obstructive pulmonary disease: a randomized trial. Ann Intern Med 2007;146:545-55
- Akazawa M, Biddle AK, Stearns SC. Economic assessment of early initiation of inhaled corticosteroids in chronic obstructive pulmonary disease using propensity score matching. Clin Ther 2008;30:1003-16
- Pauwels R, Calverley P, Buist AS, et al. COPD exacerbations: the importance of a standard definition. Respir Med 2004;98:99-107
- DiPiro JT, Talbert RL, Yee CC, et al. Pharmacotherapy: A Pathophysiologic Approach, 6th edn. New York: McGraw-Hill, 2005
- Burge S, Wedzicha J. COPD exacerbations: definitions and classifications. Eur Respir J 2003;21:46-53s
- Collett D. Modelling Survival Data in Medical Research. New York: Chapman & Hall, 1994
- Burnham KP, Anderson DR. Model Selection and Multimodel Inference: a Practical Information-Theoretic Approach, 2nd edn. New York: Springer-Verlag, 2002
- Akaike H. Information theory and an extension of the maximum likelihood principle. In: Petrov BN, Caski F, eds. Proceedings of the Second International Symposium on Information Theory. Budapest: Akademiai Kiado, 1973:267-81
- Klein JP, Moeschberger ML. Survival Analysis: Techniques for Censored and Truncated Data. New York: Springer-Verlag Inc., 1997
- Olsson U. Generalized Linear Models: An Applied Approach. Lund, Sweden: Studentlitteratur AB, 2003
- Rabe KF, Hurd S, Anzueto A, et al. Global strategy for the diagnosis, management, and prevention of chronic obstructive pulmonary disease: GOLD executive summary. Am J Respir Crit Care Med 2007;176:532-55
- Brusasco V, Hodder R, Miravitlles M, et al. Health outcomes following treatment for six months with once daily tiotropium compared with twice daily salmeterol in patients with COPD. Thorax 2003;58:399-404
- Casaburi R, Mahler DA, Jones PW, et al. A long-term evaluation of once-daily inhaled tiotropium in chronic obstructive pulmonary disease. Eur Respir J 2002;19:217-24
- Vincken W, Noord JAv, Greefhorst APM, et al. Improved health outcomes in patients with COPD during 1 year’s treatment with tiotropium. Eur Respir J 2002;19:209-16
- Aalbers R, Ayres J, Backer V, et al. Formoterol in patients with chronic obstructive pulmonary disease: a randomized, controlled, 3-month trial. Eur Respir J 2002;19:936-43
- D'Urzo AD, Salvo MCd, Ramirez-Rivera A, et al. In patients with COPD, treatment with a combination of formoterol and ipratropium is more effective than a combination of salbutamol and ipratropium: a 3-week, randomized, double-blind, within-patient, multicenter study. Chest 2001;119:1347-56
- Dahl R, Greefhorst LAPM, Nowak D, et al. Inhaled formoterol dry powder versus ipratropium bromide in chronic obstructive pulmonary disease. Am J Respir Crit Care Med 2001;164:778-84
- Rossi A, Kristufek P, Levine BE. Comparison of the efficacy, tolerability and safety of formoterol dry powder and oral, slow-release theophylline in the treatment of COPD. Chest 2002;121:1058-69
- Szafranski W, Cukier A, Ramirez A, et al. Efficacy and safety of budesonide/formoterol in the management of chronic obstructive pulmonary disease. Eur Respir J 2003;21:74-81
- Calverley PM, Boonsawat W, Cseke Z, et al. Maintenance therapy with budesonide and formoterol in chronic obstructive pulmonary disease. Eur Respir J 2003;22:912-19
- Decramer M, Celli B, Tashkin DP, et al. Clinical trial design considerations in assessing long-term functional impacts of tiotropium in COPD: the UPLIFT trial. J COPD 2004;1:303-12
- Ferguson GT, Anzueto A, Fei R, et al. Effect of fluticasone propionate/salmeterol (250/50 microg) or salmeterol (50 microg) on COPD exacerbations. Respir Med 2008;102:1099-108
- Lokke A, Lange P, Scharling H, et al. Developing COPD: a 25 year follow-up study of the general population. Thorax 2006;61:935-9
- Sin DD. Is COPD really a cardiovascular disease?. Chest 2009;136:329-30
- Niewoehner DE, Lohknygina Y, Rice K, et al. Risk indexes for exacerbations and hospitalizations due to COPD. Chest 2007;131:20-8
- Stockley RA, Chopra N, Rice L. Addition of salmeterol to existing treatment in patients with COPD: a 12 month study. Thorax 2006;61:122-8
- Rennard SI, Anderson W, ZuWallack R, et al. Use of long-acting inhaled beta2-adrenergic agonist salmeterol xinafoate in patients with chronic obstructive pulmonary disease. Am J Respir Crit Care Med 2001;163:1087-92
- Rossi A, Kristufek P, Levine BE, et al. Comparison of the efficacy, tolerability, and safety of formoterol dry powder and oral, slow-release theophylline in the treatment of COPD. Chest 2002;121:1058-69
- Hahn J. On the role of the propensity score in efficient semiparametric estimation of average treatment effects. Econometrica 1998;66:315-31